Fig. 6

Loss of TTC17 sensitizes breast cancer to rapamycin and paclitaxel. a Schematic showing the screening of drugs with a discrepancy in the efficacy on breast cancer cells by TTC17 silencing in the listed antineoplastics through CCK8 assays. b Rose plot of the composition of the signaling pathways targeted by the compounds being tested. c–d Proportions (c) and profiles of signaling networks (d) of drugs with inhibitory disparity for TTC17-knockdown and control cells. e–f Representative agents, whose inhibitory effects on breast cancer cells were enhanced (e) or attenuated (f) by TTC17 silencing, including rapamycin and paclitaxel. g-j Disease control rates of the breast cancer patients treated with rapamycin in the overall cohort (g), in subgroups with patients < 60 years of age (h), with pathological grade 1 or 2 (i), or with a combination therapy of nonsteroidal aromatase inhibitor or exemestane (j). k–m Gross image (k) and statistical analysis of volume (l) and weight (m) of the transplanted tumors extracted from BALB/c mice injected with 4T1 cells. n–o Association between TTC17 expression and pathologic complete response in breast cancer patients subjected to paclitaxel-based chemotherapy as a neoadjuvant therapy (n) or relapse-free survival at five years in breast cancer patients receiving paclitaxel-based chemotherapy as an adjuvant therapy (o)